New genetic mutation could signal start of malaria drug resistance in Africa17 April 2015 London School of Hygiene & Tropical Medicine London School of Hygiene & Tropical Medicine https://lshtm.ac.uk/themes/custom/lshtm/images/lshtm-logo-black.png
Early indicators of the malaria parasite in Africa developing resistance to the most effective drug available have been confirmed, according to new research published in Antimicrobial Agents and Chemotherapy.
Researchers at the London School of Hygiene & Tropical Medicine found Plasmodium falciparum malaria parasites with a mutation to the gene Ap2mu were less sensitive to the antimalarial drug artemisinin.
A study in 2013, also led by the School, suggested an initial link between a mutation in the ap2mu gene and low levels of malaria parasites remaining in the blood of Kenyan children after they had been treated.* However, further research was needed to confirm if these genetic characteristics represented an early step towards resistance.
In the new study, researchers genetically altered the malaria parasite in the laboratory to mutate ap2mu in the same way that had been observed in Kenya. They found the altered parasite was significantly less susceptible, requiring 32% more drug to be killed by artemisinin. The genetically altered parasite was also 42.4% less susceptible to the traditional antimalarial drug, quinine.
Earlier this year a different research group discovered mutations in the gene kelch13 which were linked to reduced susceptibility to artemisinin combination treatment in South East Asia.** Historically, resistance to antimalarial medicines has emerged in South East Asia and then spread to Africa. But these new findings suggest a different route to drug resistance may be developing independently in Africa.
Lead researcher Dr Colin Sutherland, Reader in Parasitology at the London School of Hygiene & Tropical Medicine, said: "Our findings could be a sign of much worse things to come for malaria in Africa. The malaria parasite is constantly evolving to evade our control efforts. We've already moved away from using quinine to treat cases as the malaria parasite has become more resistant to it, but if further drug resistance were to develop against our most valuable malaria drug, artemisinin, we would be facing a grave situation.
"We now know that the gene ap2mu is an important factor in determining how well our drugs kill malaria parasites. We will be conducting laboratory and field studies to more accurately measure the impact of mutations in the ap2mu gene. We hope our findings will help understand resistance of malaria to drugs, and potentially be an important tool for monitoring malaria treatment in the future."
The World Health Organization estimates more than half a million people die from malaria every year, mostly children under five. Plasmodium falciparum is the most deadly form of the malaria parasite.
- Gisela Henriques, Donelly A van Schalkwyk, Rebekah Burrow, David C. Warhurst, Eloise Thompson, David A. Baker, David A. Fidock, Rachel Hallett, Christian Flueck, Colin J. Sutherland. The mu-subunit of Plasmodium falciparum clathrin-associated adaptor protein 2 modulates in vitro parasite response to artemisinin and quinine. Antimicrobial Agents and Chemotherapy. DOI: 10.1128/AAC.04067-14
* Beshir, Sutherland et al. Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence.The Journal of infectious diseases. DOI: 10.1093/infdis/jit431
** Miotto et al. Genetic architecture of artemisinin resistant Plasmodium falciparum. Nature Genetics. DOI: 10.1038/ng.3189
Every year, LSHTM donors, alumni and friends donate to help widen access to education through the provision of scholarships.
Scholarships are transformational, have the capacity to change the lives of the students who receive them, and alleviate the financial burden of study for talented and motivated recipients.